Oral Semaglutide vs Orforglipron
Two GLP-1 pills now approved for weight loss. Oral semaglutide is Wegovy pill (Novo Nordisk). Orforglipron is Foundayo (Eli Lilly). Both are taken daily, but their timing rules and weight loss differ.
Quick read · 5 min
The main trade-off: oral semaglutide produces slightly more weight loss but requires a 30-minute fast before eating. Orforglipron produces slightly less weight loss but can be taken any time with no food restrictions. Neither is universally better — it depends on your priorities and lifestyle.
- •Oral semaglutide: up to 16.6% weight loss, but requires 30-min fasting window before food
- •Orforglipron: up to 12.4% weight loss, zero food timing restrictions — take anytime
- •Semaglutide has proven cardiovascular benefit (20% reduction in major heart events). Orforglipron does not yet have this data.
- •Both cost around $149/month self-pay; both are ~$25/month with insurance
- •No head-to-head trial exists. This is an indirect comparison based on separate trials.
No Head-to-Head Trial
There is no clinical trial directly comparing these two pills. Oral semaglutide data comes from OASIS-1 (Novo Nordisk trial). Orforglipron data comes from ATTAIN-1 and ATTAIN-2 (Eli Lilly trials). The comparison below uses data from these separate studies, which is less definitive than a head-to-head trial.
Weight Loss Comparison
Context: Oral semaglutide shows higher weight loss — roughly 10 lbs more for a 240 lb person. Individual results vary substantially. Adherence matters: oral semaglutide's 16.6% figure assumes full adherence; typical adherence gives about 13.6% in OASIS-1.
Food Timing Rules
Oral semaglutide (Wegovy pill)
Must be taken on an empty stomach with only 4 oz water or less, 30 minutes before eating or drinking anything else. This is a strict requirement for absorption. No coffee, no juice, no food for 30 minutes.
Orforglipron (Foundayo)
Zero food timing restrictions. Take it any time of day, any time of day, with or without food. You can eat immediately after. This is the main convenience advantage.
Implication: If you have an unpredictable schedule, skip breakfast, or travel across time zones, orforglipron is dramatically easier. If a 30-minute fast fits your routine, oral semaglutide is manageable.
Cardiovascular Evidence
Oral semaglutide (Wegovy pill)
The SELECT trial (n=17,604) showed 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease. This is robust evidence from the injection form; the pill likely has similar benefits but hasn't been separately tested in a cardiovascular outcomes trial.
Orforglipron (Foundayo)
Cardiovascular outcomes data is not yet available. ATTAIN trials showed improvements in blood pressure and lipids. 91% of prediabetic participants reached near-normal blood sugar vs. 42% placebo in ATTAIN-1.
Implication: If cardiovascular protection is a priority, oral semaglutide has stronger evidence. Orforglipron is still being evaluated for cardiovascular outcomes; these results are expected in the coming years.
Cost Comparison
Both are similarly priced at entry level. Orforglipron's cost varies more by dose. Both are dramatically cheaper than injectable drugs (~$1,350/month).
Side Effect Comparison
Both drugs
Nausea is most common (33-44% in trials), typically in the first 4–8 weeks during dose escalation, then subsides. Other GI side effects (diarrhea, constipation, vomiting) also common.
Oral semaglutide
Well-established safety record with longer market history. Long history of injectable semaglutide provides reassurance.
Orforglipron
Newer, smaller-molecule approach. Side effect profile appears similar to other GLP-1 drugs. Safety data from multiple Phase 3 trials (ATTAIN series) is reassuring but less extensive than long-term injectable semaglutide history.
Context: Side effect severity varies widely by individual. Neither profile is dramatically different from the other.
Trade-Off Summary
Oral Semaglutide Profile
- ✓Higher weight loss (16.6% vs 12.4%)
- ✓Proven cardiovascular benefit (20% reduction in major events)
- ✓Longer market history — extensive safety data
- ◆Strict 30-minute fasting window — no food or water
- ◆Less convenient for unpredictable schedules or travel
- ◆Adherence challenges affect real-world weight loss
Orforglipron Profile
- ✓Zero food timing restrictions — take anytime
- ✓Much simpler schedule for busy or unpredictable routines
- ✓First small-molecule GLP-1 pill (novel mechanism)
- ◆Slightly lower weight loss (12.4% vs 16.6%)
- ◆No cardiovascular outcomes data yet (being studied)
- ◆Newer drug — less long-term follow-up data
These two pills differ in weight loss (oral semaglutide higher), convenience (orforglipron much simpler), and cardiovascular evidence (semaglutide proven, orforglipron pending). Neither is universally "better" — they suit different priorities and lifestyles. A doctor can help you decide based on your medical history, schedule, and what matters most to you.
Common Questions
Not sure where to start? Our 2-minute quiz can help.
Take the quiz →Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026